Avalo Therapeutics reported a third-quarter 2026 net loss of $18.9 million, or $0.34 per share, compared to a $30.6 million loss in the prior-year period. The improvement was primarily driven by a change in fair value related to a derivative liability, partially offset by increased research and development expenses of $15.0 million and general and administrative costs of $8.4 million. As of September 30, 2026, the company held $462.8 million in cash, cash equivalents, and investments, which management expects will fund operations into 2029. The company also provided updates on its pipeline, noting plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in the first half of 2027 and an IND submission for AVTX-010 during the same period. Avalo Therapeutics is a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases.
